RedHill Biopharma Financials

RedHill Biopharma Stock Summary

RedHill Biopharma competes with NETGEAR, Air Lease, Wizz Air, Alaska Air, and AerSale Corp. RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel. Redhill Biopharma is traded on OTC Exchange in the United States.

RedHill Biopharma Key Financial Ratios

Generally speaking, RedHill Biopharma's financial ratios allow both analysts and investors to convert raw data from RedHill Biopharma's financial statements into concise, actionable information that can be used to evaluate the performance of RedHill Biopharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that RedHill Biopharma reports annually and quarterly.

RedHill Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining RedHill Biopharma's current stock value. Our valuation model uses many indicators to compare RedHill Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across RedHill Biopharma competition to find correlations between indicators driving RedHill Biopharma's intrinsic value. More Info.RedHill Biopharma is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value RedHill Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for RedHill Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the RedHill Biopharma's earnings, one of the primary drivers of an investment's value.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

If you are still planning to invest in RedHill Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RedHill Biopharma's history and understand the potential risks before investing.